Carisma Therapeutics price target lowered to $9 from $11 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Carisma Therapeutics to $9 from $11 and keeps a Buy rating on the shares following the Q4 report. The company announced a strategic shift in pipeline priorities and certain changes in ongoing program efforts, the analyst tells investors in a research note. The firm says the most important update is is CT-0508 will be discontinued in favor of CT-0525 development.